PIXCLARA Drug Patent Profile
When do Pixclara patents expire, and when can generic versions of Pixclara launch?
Pixclara is a drug marketed by Telix and is included in one NDA.
The generic ingredient in PIXCLARA is floretyrosine f-18. One supplier is listed for this compound. Additional details are available on the floretyrosine f-18 profile page.
US Patents and Regulatory Information for PIXCLARA
PIXCLARA is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of PIXCLARA is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Telix | PIXCLARA | floretyrosine f-18 | SOLUTION;INTRAVENOUS | 218592-001 | Sep 11, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
